Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 14/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24061152 | 0.83 | L3MBTL1 (0.62) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL11184622 | 0.82 | L3MBTL1 (0.61) | L3MBTL1MTNR1AMTNR1BKDM4EALDH1A1 | |
| SCHEMBL24061162 | 0.82 | L3MBTL1 (0.61) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL26378357 | 0.80 | MEN1 (0.45) | KDM4EALDH1A1SMN1; SMN2LMNANSD2 | |
| SCHEMBL18737436 | 0.77 | CA12 (0.54) | KDM4EALDH1A1SMN1; SMN2LMNANSD2 | |
| SCHEMBL11180030 | 0.76 | ACHE (0.54) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL17164162 | 0.76 | L3MBTL1 (0.68) | L3MBTL1MTNR1AMTNR1BKDM4E | |
| Ammonia Solution, Strong SCHEMBL11181888 | 0.75 | ACHE (0.53) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL11178103 | 0.75 | ACHE (0.56) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL17164001 | 0.75 | L3MBTL1 (0.75) | L3MBTL1MTNR1AMTNR1BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÉ DE TOURS (FR) | 2023-10-05 | — | — | US | disclosed |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÉ DE TOURS (FR) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | LIMK1, LIMK2, ROCK1 | L3MBTL1 3922/4885MTNR1A 3125/4885MTNR1B 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.